What Is GHRP-6? Benefits, Research & Safety
The first clinically evaluated growth hormone-releasing peptide, notable for its potent GH release and pronounced appetite-stimulating effects.
UK summary: Not a licensed UK medicine. Growth-hormone-releasing peptide with additional appetite-stimulating effect (it activates the ghrelin receptor). Prohibited at all times under WADA S2.
Quick Facts
Overview
GHRP-6 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Growth-hormone-releasing peptide with additional appetite-stimulating effect (it activates the ghrelin receptor). Prohibited at all times under WADA S2.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed for human use. Research compound only.
- EU: Not approved for therapeutic use.
- Notes: GHRP-6 is not approved by any regulatory authority for therapeutic use. It is prohibited in sports by WADA. Available only as a research compound.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Stimulates GH safely for muscle gain and recovery.
- Boosts appetite for hardgainers without side effects.
- Safe for daily long-term cycling.
- Undetectable by drug tests.
07Common internet claims
- Marketed in bodybuilding stacks for bulking phases.
- Sold online as an appetite-stimulating GH secretagogue.
- Promoted as the original GHRP and 'cheaper than HGH'.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Stimulates appetite for muscle-building cycles” | D | Limited | High | Ghrelin-receptor activation does increase appetite acutely; this is not a licensed indication or a safe long-term strategy. |
| “Boosts GH and IGF-1 like CJC-1295 but with appetite bonus” | D | Limited | High | Short-term GH response is documented; the 'appetite bonus' framing is marketing, not a licensed therapeutic claim. |
| “Safe long-term for healthy adults” | E | No | High | Long-term human safety in healthy adults is not established. |
09Safety uncertainty score
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Intense appetite stimulation (defining effect; may be unwanted).
- Cortisol and prolactin elevation.
- Water retention, joint pain, carpal tunnel symptoms.
- Theoretical oncologic risk from sustained IGF-1 elevation.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed for human use. Research compound only.
14EU legal position
Not approved for therapeutic use.
15What this page cannot tell you
- Whether a UK-purchased vial contains GHRP-6 at the labelled concentration.
- Whether the hunger response represents real physiologic ghrelin activation or a contaminant.
- What chronic ghrelin-receptor activation does to metabolic and oncologic risk.
- WADA detection windows — assume positive on test, prohibition is strict-liability.
16Last reviewed
17Citation quality score
18Research gaps
- No Phase 3 trials for any indication in healthy adults.
- Long-term safety beyond a few months absent.
- Combination-stack safety uncharacterised.
- Cancer-surveillance data unavailable.
19Safer alternatives / established care pathways
- Endocrinologist review and formal GH-deficiency testing if clinically suspected.
- Licensed recombinant HGH under specialist supervision where confirmed.
- Calorie surplus, resistance training, and protein-adequate diet for body-composition goals.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is GHRP-6 a licensed UK medicine?
- What's the WADA / UKAD position for athletes?
- What are the theoretical risks of chronic ghrelin-receptor activation?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent stimulation of growth hormone release
- 2Elevated IGF-1 levels
- 3Significant appetite stimulation (beneficial for underweight individuals)
- 4Potential cardioprotective effects
- 5Possible improvements in body composition with proper nutrition
- 6Synergistic effects with GHRH analogues
Claim vs Evidence
How popular claims about GHRP-6 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Stimulates appetite for muscle-building cycles” | D | Limited | High | Ghrelin-receptor activation does increase appetite acutely; this is not a licensed indication or a safe long-term strategy. |
| “Boosts GH and IGF-1 like CJC-1295 but with appetite bonus” | D | Limited | High | Short-term GH response is documented; the 'appetite bonus' framing is marketing, not a licensed therapeutic claim. |
| “Safe long-term for healthy adults” | E | No | High | Long-term human safety in healthy adults is not established. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 100-300 mcg per dose |
| Frequency | 2-3 times daily, typically before meals |
| Duration | Variable; often cycled |
| Notes | GHRP-6 is not approved for therapeutic use. Its strong appetite stimulation should be considered—it may not be appropriate for those trying to limit food intake. Any use should be under medical supervision. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (most common)
| Half-Life | Stability |
|---|---|
| Approximately 15-20 minutes | Lyophilised powder stable when properly stored; reconstituted solution should be refrigerated |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Intense hunger (very common)
- Water retention
- Injection site reactions
- Flushing
- Tingling or numbness
- Transient cortisol elevation
Rare Risks & Concerns
- Effects on blood glucose
- Unknown long-term effects
- Potential issues with chronic cortisol elevation
- Theoretical concerns with tumour growth
Contraindications
- Active malignancy
- Pregnancy and breastfeeding
- Diabetes (monitor closely)
- Eating disorders (appetite effects)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. Research compound only.
🇪🇺 European Union
Not approved for therapeutic use.
Clinical Studies Summary
GHRP-6 and Cardiac Protection
Research demonstrating cardioprotective effects of GHRP-6 in ischemia models.
Looking for GHRP-6?
Source research-grade GHRP-6 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about GHRP-6
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is GHRP-6 a licensed UK medicine?
- What's the WADA / UKAD position for athletes?
- What are the theoretical risks of chronic ghrelin-receptor activation?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Combination Protocols
Related Peptides
CJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn moreGHRP-2
A potent growth hormone-releasing peptide that stimulates GH secretion through the ghrelin receptor, with additional effects on appetite and cortisol.
Learn moreHexarelin
A potent growth hormone-releasing peptide with notable cardioprotective properties independent of GH release.
Learn more